Moderate-to-severe pruritus and expression of pruritic and inflammatory biomarkers in atopic dermatitis decreased by oral difelikefalin
In this medfyle
A phase 2 clinical trial concluded that oral difelikefalin reduced itch in moderate-to-severe AD-related pruritus, particularly in the itch-dominant AD phenotype. The drug impacted the expression of TH2-associated genes, inflammatory biomarkers, upregulating the expression of claudins and lipid metabolism-associated genes, with a restoration of the skin barrier integrity and clinical improvement.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
©2024 Medfyle. All rights reserved.
Original article:
Guttman-Yassky E, Facheris P, Da Rosa JC, Rothenberg-Lausell C, Del Duca E, David E, Estrada Y, Liu Y, Bose S, Chowdhury M, Munera C, Goncalves J, Nograles K, Kim BS, Lebwohl M. Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis. J Allergy Clin Immunol. 2023 Oct;152(4):916-926. doi: 10.1016/j.jaci.2023.06.023. Epub 2023 Jul 13. PMID: 37453614.
The summary was prepared by Marta Castano for Medfyle and reviewed by Martina Lambertini, MD.
The authors of the original article, the journal and the publisher were not involved in the creation of the summary.
